NeoGenomics (NEO) – Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for NeoGenomics (NASDAQ: NEO):

• 10/31/2026 – NeoGenomics was downgraded by Wall Street Zen from “buy” to “hold”.
• 10/29/2026 – NeoGenomics had its price target raised by TD Cowen from $19.00 to $23.00. They now have a “buy” rating on the stock.
• 10/29/2026 – NeoGenomics had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $21.00 price target on the stock.
• 10/29/2026 – NeoGenomics had its “buy” rating reaffirmed by BTIG Research. They now have a $28.00 price target on the stock.
• 10/12/2026 – NeoGenomics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/7/2026 – NeoGenomics had its “overweight” rating reaffirmed by Piper Sandler.
• 10/6/2026 – NeoGenomics had its price target raised by Needham & Company LLC from $19.00 to $22.00. They now have a “buy” rating on the stock.
• 9/28/2026 – NeoGenomics was downgraded by Zacks Research from “strong-buy” to “hold”.

NeoGenomics Price Performance

Shares of NASDAQ:NEO opened at $16.49 on Friday. NeoGenomics, Inc. has a twelve month low of $7.07 and a twelve month high of $20.15. The company’s 50 day moving average is $17.67 and its 200 day moving average is $12.90. The company has a current ratio of 3.53, a quick ratio of 3.31 and a debt-to-equity ratio of 0.47. The company has a market cap of $2.13 billion, a PE ratio of -65.96 and a beta of 1.87.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Wednesday, October 28th. The medical research company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.06 by $0.01. The business had revenue of $209.25 million during the quarter, compared to analysts’ expectations of $206.70 million. NeoGenomics had a negative net margin of 4.10% and a negative return on equity of 0.99%. The business’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.03 EPS. On average, sell-side analysts forecast that NeoGenomics, Inc. will post -0.06 EPS for the current year.

NeoGenomics, Inc (NASDAQ: NEO) is a cancer-focused diagnostics company that provides laboratory testing and related services to oncologists, hospitals, academic institutions, and biopharmaceutical companies. Its diagnostic offerings support the detection, classification, and monitoring of cancer and help inform treatment decisions.

The company’s services include pathology, immunohistochemistry, flow cytometry, cytogenetics, molecular testing, and other specialized oncology assays. NeoGenomics also provides clinical trial and pharmaceutical services, including biomarker testing, central laboratory support, and companion diagnostic development for drug developers.

Founded in 1999, NeoGenomics has expanded through internal growth and acquisitions and operates a network of clinical laboratories serving customers primarily in the United States, with additional international capabilities.